製品: PCK1 Antibody
カタログ: DF6770
タンパク質の説明: Rabbit polyclonal antibody to PCK1
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Bovine, Sheep, Rabbit, Dog
分子量: 69kDa; 69kD(Calculated).
ユニプロット: P35558
RRID: AB_2838732

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Bovine(83%), Sheep(83%), Rabbit(83%), Dog(83%)
クローナリティ:
Polyclonal
特異性:
PCK1 Antibody detects endogenous levels of total PCK1.
RRID:
AB_2838732
引用形式: Affinity Biosciences Cat# DF6770, RRID:AB_2838732.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

cytosolic [GTP]; GTP; PCK1; PCKGC_HUMAN; PEP carboxykinase; PEPCK-C; PEPCK1; PEPCKC; Phosphoenolpyruvate carboxykinase 1 (soluble); Phosphoenolpyruvate carboxykinase 1; Phosphoenolpyruvate carboxykinase; Phosphoenolpyruvate carboxykinase, cytosolic [GTP]; Phosphoenolpyruvate carboxykinase, cytosolic; Phosphoenolpyruvate carboxylase; Phosphopyruvate carboxylase;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
P35558 PCKGC_HUMAN:

Major sites of expression are liver, kidney and adipocytes.

タンパク質の説明:
PCK1(Phosphoenolpyruvate carboxykinase, cytosolic) is also named as PEPCK1 and belongs to the phosphoenolpyruvate carboxykinase [GTP] family. It catalyzes the formation of phosphoenolpyruvate from oxaloacetate, with the release of carbon dioxide and GDP. It is also a main control point for the regulation of gluconeogenesis. In eukaryotes there are two isozymes: a cytoplasmic one and a mitochondrial one. Defects in PCK1 are the cause of cytosolic phosphoenolpyruvate carboxykinase deficiency (C-PEPCKD). This antibody is specific to PCK1.
タンパク質配列:
MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPVLEAVGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSLLGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
83
Sheep
83
Dog
83
Rabbit
83
Horse
75
Xenopus
67
Chicken
67
Pig
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P35558 基板として

Site PTM Type Enzyme
S19 Phosphorylation
K70 Acetylation
K71 Acetylation
K91 Acetylation
T178 Phosphorylation
S233 Phosphorylation
Y235 Phosphorylation
K243 Ubiquitination
K473 Acetylation
Y557 Phosphorylation
K594 Acetylation

研究背景

機能:

Regulates cataplerosis and anaplerosis, the processes that control the levels of metabolic intermediates in the citric acid cycle. At low glucose levels, it catalyzes the cataplerotic conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. At high glucose levels, it catalyzes the anaplerotic conversion of phosphoenolpyruvate to oxaloacetate.

PTMs:

Acetylated. Lysine acetylation by p300/EP300 is increased on high glucose conditions. Lysine acetylation promotes ubiquitination by UBR5. Acetylation is enhanced in the presence of BAG6. Deacetylated by SIRT2. Deacetylation of Lys-91 is carried out by SIRT1 and depends on PCK1 phosphorylation levels.

Phosphorylated in a GSK3B-mediated pathway; phosphorylation affects the efficiency of SIRT1-mediated deacetylation, and regulates PCK1 ubiquitination and degradation.

Ubiquitination by UBR5 leads to proteasomal degradation.

細胞の位置付け:

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Major sites of expression are liver, kidney and adipocytes.

サブユニット構造:

Monomer.

タンパク質ファミリー:

Belongs to the phosphoenolpyruvate carboxykinase [GTP] family.

研究領域

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Metabolism > Carbohydrate metabolism > Glycolysis / Gluconeogenesis.

· Metabolism > Carbohydrate metabolism > Citrate cycle (TCA cycle).

· Metabolism > Carbohydrate metabolism > Pyruvate metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

· Organismal Systems > Excretory system > Proximal tubule bicarbonate reclamation.

参考文献

1). Retinal metabolism displays evidence for uncoupling of glycolysis and oxidative phosphorylation via Cori-, Cahill-, and mini-Krebs-cycle. eLife, 2024 (PubMed: 38739438) [IF=7.7]

Application: IF/ICC    Species: Mouse    Sample:

Figure 6. Metabolomic comparison between control, 1,9-dideoxyforskolin (1,9-DDF), and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) treatment. (A) Heatmap illustrating 29 statistically significant metabolite changes (parametric one-way ANOVA, Fisher’s LSD post hoc analysis). Three main clusters of metabolite changes were evident (dashed lines). (B) Immunostaining (green) for enzymes related to glutamine metabolism. DAPI (grey) was used as nuclear counterstain. (B1) Glutamine synthase (GS), (B2) glutaminase C (GAC); co-localisation with cone-arrestin (Arr3; magenta). (B3) Phosphoenolpyruvate carboxykinase 1 (PCK1) did not co-localise with cone marker peanut agglutinin (PNA) while (B4) PCK2 did. (C) Ratios between metabolites representing glycolysis (lactate vs. guanosine triphosphate [GTP]), anaplerotic metabolism (GTP vs. branched chain amino acids [BCAA]), and serine synthesis pathway (serine vs. lactate). Data represented as individual data points with mean ± SD (n=5).

2). Nr2e1 ablation impairs liver glucolipid metabolism and induces inflammation, high-fat diets amplify the damage. Biomedicine & Pharmacotherapy, 2019 (PubMed: 31590127) [IF=4.8]

Application: WB    Species: mouse    Sample: liver

Fig. 3. |Nr2e1 deficiency impaired glucose tolerance and insulin sensitivity, the damages were exacerbated by HFD.Western blots measured the expression of phosphorylated protein of IRS1, AKT, GSK3β and FOXO1 in the liver samples after 12 weeks of HFD or SD feeding (3 H). Phosphorylated protein levels were normalized to the respective total protein levels (3I).

3). Mechanism of N-Methyl-N-Nitroso-Urea-Induced Gastric Precancerous Lesions in Mice. Journal of Oncology, 2022 (PubMed: 35342404)

4). Mechanism of Hypoxia-Activated MiR-194 /FoxO3a Inducing Glycolytic Metabolism Reprogramming in Gastric Precancerous Lesions. Research Square, 2021

Application: WB    Species: Mouse    Sample: gastric mucosa

Figure 6. Changes in expression levels of key proteins in the FoxO3a signaling pathway in Figure 6. Changes in expression levels of key proteins in the FoxO3a signaling pathway in gastric mucosa. A, immunoblot showing protein expression levels of P-FoxO3a, FoxO3a, P-AMPK, AMPK, PCK1, LKB1, and LDHA. B, The ratio of P-FoxO3a/FoxO3a is lower, P-AMPK/AMPK and P-AKT/AKT are higher in GPL.C, The PCK1, LKB1 decreased, and LDHA overexpressed in GPL,. A, immunoblot showing protein expression levels of P-FoxO3a, FoxO3a, P-AMPK, AMPK, PCK1, LKB1, and LDHA. B, The ratio of P-FoxO3a/FoxO3a is lower, P-AMPK/AMPK and P-AKT/AKT are higher in GPL.C, The PCK1, LKB1 decreased, and LDHA overexpressed in GPL,

5). The retina uncouples glycolysis and oxidative phosphorylation via Cori-, Cahill-, and mini-Krebs-cycle. bioRxiv, 2023

Application: IF/ICC    Species: Fish    Sample:

Figure 10 Metabolomic comparison between control, 1,9-DDF, and FCCP treatment. (A) Heatmap illustrating 29 statistically significant metabolite changes (parametric one-way ANOVA, Fisher’s LSD post-hoc analysis). Three main clusters of metabolite changes were evident (dashed lines). (B) Immunostaining (green) for enzymes related to glutamine metabolism. DAPI (grey) was used as nuclear counterstain. (B1) Glutamine synthase (GS), (B2) glutaminase C (GAC); co-localization with cone-arrestin (Arr3; magenta). (B3) phosphoenolpyruvate carboxykinase 1 (PCK1) did not co-localize with cone marker peanut-agglutinin (PNA) while (B4) PCK2 did. (C) Ratios between metabolites representing glycolysis (lactate vs. GTP), anaplerotic metabolism (GTP vs. BCAA), and serine synthesis pathway (serine vs. lactate). Data represented as individual data points with mean ± SD. Statistical testing: One-way ANOVA with Tukey’s post-hoc test; p-values: **** < 0.0001, *** < 0.001, ** < 0.01 * < 0.05. See also Supplementary.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.